Moderna (MRNA) call put ratio 1 calls to 1.9 puts after INTerpath-001 trial results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro boost AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
Moderna (MRNA) PT Raised to $89 at Morgan Stanley
August 19, 2026 4:23 PM EDTMorgan Stanley analyst Terence Flynn raised the price target on Moderna (NASDAQ: MRNA) to $89.00 (from $39.00) while maintaining a Equalweight rating.
The analyst comments "We are Equal-weight Moderna. While we believe there is long-term upside for Moderna, we believe the significant valuation increase... More



